is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments for life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development. Founded in 2013, the company operates within the Biotechnology, Health Care, and Pharmaceutical industries. Its last investment at 29 February 2024 amounted to £3.33MPost-IPO Equity, signaling a promising trajectory. The investors behind the last investment were not disclosed.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | £3.33M | - | 29 Feb 2024 | |
| Post-IPO Equity | £668.00K | 1 |
|
18 Sep 2023 |
| Post-IPO Equity | $4.06M | - | 26 Jan 2023 | |
| Post-IPO Debt | $60.00M | 1 | Mint Capital | 18 Nov 2020 |
| Post-IPO Equity | $1.00M | - | 29 Jun 2016 |
We care about your data, and we'd love to use cookies make your experience better.
